^
Association details:
| Biomarker: | STK11 negative + LGALS3 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
7P - STK11 and Galectin-3 Tissue Expression Entails a Prognostic Signature in Immunotherapy Treated NSCLC patients
Published date:
03/17/2021
Excerpt:
Patients carrying STK11neg/Gal-3 high tumors had significantly reduced PFS (mPFS, 1.7 vs 13.5 months, P = 0.001) and lower benefit from ICI (DCR, 30% vs 80%, P = 0.03) compared to their counterpart....STK11neg and Gal-3high may represent a poor prognostic trait in ICI-treated NSCLC patients.
